Photo by lcma1028 from unsplash
It is estimated that about 66% of the number of people with dementia globally live in regions within the low-and-middle-income countries (LMIC). The estimates further suggest that about 1 million… Click to show full abstract
It is estimated that about 66% of the number of people with dementia globally live in regions within the low-and-middle-income countries (LMIC). The estimates further suggest that about 1 million additional cases are recorded annually in these LMICs, with approximately 60-70% of the dementia cases being due to Alzheimer disease, AD [1]. Despite this high incidence of AD, treatment options are currently limited. This is notwithstanding the fact that numerous clinical trials have taken place, are still on going or planned [2]. However, the rate of failure of clinical trials and predictions based on available results from randomised control trials suggest that an immediate breakthrough to obtaining treatment drugs for AD is unlikely [3].
Journal Title: Journal of Global Health
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!